Core Points - Zhonghong Medical (300981.SZ) closed at 14.21 yuan, with a decline of 2.07%, and a total market capitalization of 6.094 billion yuan, currently in a state of breaking issue [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1] - The highest price recorded on the first day of trading was 159.80 yuan, marking the peak since its listing, followed by a downward trend in stock price [1] - The total funds raised from the IPO amounted to 2.025 billion yuan, with a net amount of 1.896 billion yuan, exceeding the originally planned fundraising by 1.317 billion yuan [1] - The initial fundraising plan was to raise 580 million yuan for the production of nitrile gloves and to supplement working capital [1] Financial Distribution - The total issuance costs for the IPO were 128 million yuan, with underwriting and sponsorship fees amounting to 107 million yuan [2] - For the 2022 fiscal year, the profit distribution plan included a cash dividend of 7.00 yuan per 10 shares (tax included) and a capital reserve transfer of 3 shares for every 10 shares, resulting in a total cash dividend of 210,004,200 yuan [2] - The total share capital increased by 90,001,800 shares following the 2022 distribution [2] - For the 2021 fiscal year, the profit distribution plan included a cash dividend of 30.00 yuan per 10 shares (tax included) and a capital reserve transfer of 8 shares for every 10 shares, leading to a total cash dividend of 500,010,000 yuan [2] - The total share capital increased by 133,336,000 shares after the 2021 distribution [2] Future Projections - The 2024 profit distribution plan, announced for June 20, 2025, proposes a cash dividend of 2.5 yuan per 10 shares (tax included) and a capital reserve transfer of 1 share for every 10 shares, totaling a cash dividend of 97,142,899.50 yuan [3] - The total share capital is projected to increase to 428,864,960 shares after the 2024 distribution [3]

格隆汇11月27日丨中红医疗(300981.SZ)公布，子公司江西科伦医疗器械制造有限公司于近期取得国家 药品监督管理局颁发的《中华人民共和国医疗器械注册证》，上述注册证为原有产品的延续注册，有效 期限由原2025年10月26日到期延续至2030年11月24日到期。上述医疗器械注册证有效期的延长，延续了 公司及子公司在一次性使用无菌低阻力注射器（带针）领域的产品品类，能够保证原有产品的持续销 售，并将进一步增强公司及子公司的综合竞争力，不断满足多元化的市场需求，有利于进一步提高市场 拓展能力。 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-103 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证》，上述注册证为原有产品的延续注册，有效期限由原 2025 年 10 月 26 日到期延续至 2030 年 11 月 24 日到期。上述注册证具体情况如下： 1. 《中华人民共和国医疗器械注册证》。 一、基本信息 | 注册人名称 | 产品名称 | 注册证编号 | 注册分类 | 注册证有效期 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 江西科伦医 疗器械制造 | 一次性使用无 菌低阻力注射 | 国械注准 | Ⅲ类 | 2025年 11 月 25日至 | 本 产 品 供 抽 吸 液 体 或 在 注 入 液 体 | | | | 20153142230 | | 2030 年 11 月 24 日 | | | 有限公司 | 器 带针 | | | | 后立即注射用。 | 二、对公司的影响及风险提示 上述医疗器械注册证有效期 ...

投资者提问：董秘你好，天猫、京东、拼多多等电商平台上的"倍力乐"旗舰店是公司的品牌么？ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，中红医疗(300981)11月27日在投资者关系平台上答复投资者关心的问题。 中红医疗回复：尊敬的投资者，您好！"倍力乐"为公司旗下避孕套品牌。"中红"及"倍力乐"为中红医疗 旗下避孕套产品的两大核心品牌，其产品涵盖聚氨酯、聚异戊二烯、天然乳胶等多种材质。感谢您对公 司的关注。 ...

Core Viewpoint - Zhonghong Medical (300981.SZ) is currently experiencing a decline in stock price, closing at 14.59 yuan with a drop of 3.63%, indicating a state of breaking down since its IPO in April 2021 [1] Group 1: IPO and Initial Performance - Zhonghong Medical was listed on the Shenzhen Stock Exchange's ChiNext on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1][2] - On its first trading day, the stock reached a peak price of 159.80 yuan, marking the highest price since its listing, but has since experienced a downward trend [2] - The total funds raised from the IPO amounted to 2.025 billion yuan, with a net amount of 1.896 billion yuan, exceeding the originally planned fundraising by 1.317 billion yuan [2] Group 2: Use of Proceeds and Financial Performance - The initial plan for the raised funds was 580 million yuan, allocated for the nitrile glove project at Jiangxi Zhonghong Pulin Medical Products Co., Ltd. and for supplementing working capital [2] - The total issuance costs for the IPO were 128 million yuan, with underwriting and sponsorship fees accounting for 107 million yuan [3] Group 3: Dividend Distribution - In 2022, the company announced a profit distribution plan, distributing 7.00 yuan in cash per 10 shares (including tax) and increasing the total share capital by 9 million shares through capital reserve [3] - For the 2021 fiscal year, the company distributed 30.00 yuan in cash per 10 shares (including tax) and increased the total share capital by 13.33 million shares [3] - A future dividend plan for June 10, 2025, includes a distribution of 2.5 yuan in cash per 10 shares (pre-tax) and a share increase of 1 share for every 10 shares held [4]

Core Viewpoint - 中红医疗 is experiencing a decline in stock price and trading volume, with a market capitalization of 6.257 billion yuan and a trading volume of 188 million yuan on November 26, showing a decrease of 3.63% [1] Group 1: Business Overview - 中红医疗 specializes in the research, production, and sales of high-quality medical and industrial disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9] - The company primarily engages in ODM direct sales, producing medical devices and consumables for overseas brand owners, who handle packaging design and marketing [3] - As of September 30, 中红医疗 reported an overseas revenue share of 81.56%, benefiting from the depreciation of the yuan [4] Group 2: Recent Developments - 中红医疗 is collaborating with 桂林理工大学 to develop a multi-layer nuclear radiation protective glove, addressing the technical needs outlined in its 2024 ESG report [2] - The company showcased its veterinary infusion pumps at the 12th Beijing Pet Expo, which received positive feedback for their safety and multifunctionality [2] Group 3: Financial Performance - For the period from January to September 2025, 中红医疗 achieved a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% [10] - Since its A-share listing, 中红医疗 has distributed a total of 1.251 billion yuan in dividends, with 501 million yuan in the last three years [11] Group 4: Shareholder Information - As of September 30, 2025, 中红医疗 had 22,400 shareholders, an increase of 11.24%, with an average of 17,531 circulating shares per person, a decrease of 10.11% [10] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and a newly entered medical device ETF [11]

Core Viewpoint - Zhonghong Medical has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1] Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, including nitrile and PVC gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9] - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9] - As of September 30, 2025, Zhonghong Medical reported a total revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10] Group 2: Market Position and Strategy - The company primarily focuses on export sales and adopts an ODM direct sales model, producing medical devices and consumables for overseas brand owners who handle packaging design and marketing [3] - As of the 2024 annual report, overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the Chinese yuan [4] - Zhonghong Medical is a state-owned enterprise, ultimately controlled by the Xiamen Municipal Government's State-owned Assets Supervision and Administration Commission [5] Group 3: Product Development and Innovation - The company is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, which includes a chemical protective layer, a white warning layer, and a nuclear radiation protective layer [2] - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing various infusion modes and safety features [2]

Group 1 - The core viewpoint of the news is that Zhonghong Medical has experienced fluctuations in its stock performance and financing activities, indicating a high level of trading activity and potential investor interest [1][2]. - On November 21, Zhonghong Medical's stock fell by 2.39%, with a trading volume of 259 million yuan. The net financing purchase on that day was 1.21 million yuan, with a total financing and securities balance of 128 million yuan [1]. - The financing balance of Zhonghong Medical is currently at 128 million yuan, accounting for 2.08% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1]. Group 2 - As of September 30, Zhonghong Medical reported a total of 22,400 shareholders, an increase of 11.24% from the previous period, while the average circulating shares per person decreased by 10.11% to 17,531 shares [2]. - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38%. However, the net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [2]. - Since its A-share listing, Zhonghong Medical has distributed a total of 1.251 billion yuan in dividends, with 501 million yuan distributed in the last three years [3].

Core Viewpoint - The company, Zhonghong Medical, is experiencing a decline in stock price and has a significant portion of its revenue coming from overseas sales, benefiting from the depreciation of the RMB. The company is involved in the development of innovative medical products and has a strong focus on export-oriented ODM production. Group 1: Company Overview - Zhonghong Medical is primarily engaged in the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves for medical and industrial use [9] - The company was established on December 22, 2010, and went public on April 27, 2021 [9] - As of September 30, the company had 22,400 shareholders, with an average of 17,531 circulating shares per person, a decrease of 10.11% from the previous period [10] Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38% [10] - The net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10] - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed in the last three years [11] Group 3: Market Position and Trends - The company’s overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4] - Zhonghong Medical is classified as a state-owned enterprise, with its ultimate controller being the State-owned Assets Supervision and Administration Commission of the Xiamen Municipal Government [5] - The company is involved in various sectors, including nuclear pollution prevention, pet economy, and medical device concepts [2]

Market Overview - The Shanghai Composite Index rose by 0.18% on November 19, with 10 industries experiencing gains, led by non-ferrous metals and petroleum & petrochemicals, which increased by 2.39% and 1.67% respectively. Conversely, the comprehensive and real estate sectors saw declines of 3.08% and 2.09% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 40.955 billion yuan across the two markets, with 7 industries experiencing net inflows. The defense and military industry led with a net inflow of 3.610 billion yuan and a daily increase of 1.11%, followed by the banking sector with a 0.92% increase and a net inflow of 1.265 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector declined by 1.28%, with a total net outflow of 4.880 billion yuan. Out of 477 stocks in this sector, 44 rose, including 3 that hit the daily limit, while 431 fell, with 4 hitting the lower limit. Notably, 90 stocks had net inflows, with Dongfang Ocean leading at 245 million yuan [2][4] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Dongfang Ocean: +9.96% with a net inflow of 24.473 million yuan - Yaoming Kangde: +0.95% with a net inflow of 7.010 million yuan - Zhonghong Medical: +10.39% with a net inflow of 6.370 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: -4.73% with a net outflow of 234.806 million yuan - Maijie Medical: -0.92% with a net outflow of 173.607 million yuan - Hainan Haiyao: -10.00% with a net outflow of 156.557 million yuan [4]